Fluoropyrimidine-Induced Severe Toxicities Associated with Rare DPYD Polymorphisms: Case Series from Saudi Arabia and a Review of the Literature

被引：5

作者：

Bukhari, Nedal ^{[1
,2
]}

Alshangiti, Abdulraheem ^{[1
]}

Tashkandi, Emad ^{[3
,4
]}

Algarni, Mohammed ^{[5
,6
]}

Al-Shamsi, Humaid O. ^{[7
,8
,9
]}

Al-Khallaf, Hamoud ^{[10
]}

机构：

[1] King Fahad Specialist Hosp, Dept Med Oncol, Dammam 31444, Saudi Arabia

[2] Imam Abdulrahman Bin Faisal Univ, Dept Internal Med, Dammam 34212, Saudi Arabia

[3] King Abdullah Med City, Oncol Ctr, Mecca 24246, Saudi Arabia

[4] Umm Al Qura Univ, Coll Med, Mecca 24211, Saudi Arabia

[5] King Abdul Aziz Med City, Oncol Dept, Riyadh 11426, Saudi Arabia

[6] King Saud bin Abdulaziz Univ Hlth Sci, Riyadh 11481, Saudi Arabia

[7] Burjeel Med City, Burjeel Canc Inst, Dept Oncol, Abu Dhabi 999041, U Arab Emirates

[8] Emirates Oncol Soc, Dubai 22107, U Arab Emirates

[9] Univ Sharjah, Coll Med, Sharjah 999041, U Arab Emirates

[10] King Fahad Specialist Hosp, Dept Pathol & Lab Med, Dammam 31444, Saudi Arabia

来源：

CLINICS AND PRACTICE | 2021年 / 11卷 / 03期

关键词：

dihydropyrimidine dehydrogenase; 5-Fluorouuracil; chemotherapy; DPYD; polymorphism; CAPECITABINE; VARIANTS; SAFETY;

D O I：

10.3390/clinpract11030062

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Dihydropyrimidine dehydrogenase (DPD) is the major enzyme in the catabolism of 5-Fluorouracil (5-FU) and its prodrug capecitabine. We report cases from our institute with colorectal cancer who experienced severe toxicities to standard dose 5-FU based chemotherapy. DPYD gene sequencing revealed rare different polymorphisms that prompted dose adjustments of administered 5-FU and capecitabine. To our knowledge, this is the first case series looking at DPYD polymorphisms in the Saudi Arabian population.

引用

页码：467 / 471

页数：5

共 20 条

[1]

Al Khallaf Hamoud H, 2013, Indian J Hum Genet, V19, P483, DOI 10.4103/0971-6866.124382

[2] Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update [J].

Amstutz, Ursula ;

Henricks, Linda M. ;

Offer, Steven M. ;

Barbarino, Julia ;

Schellens, Jan H. M. ;

Swen, Jesse J. ;

Klein, Teri E. ;

McLeod, Howard L. ;

Caudle, Kelly E. ;

Diasio, Robert B. ;

Schwab, Matthias .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 (02) :210-216

[3]

Bukhari Nedal, 2019, Case Rep Genet, V2019, P5150725, DOI 10.1155/2019/5150725

[4] Cost-effectiveness of screening for DPYD polymorphisms to prevent neutropenia in cancer patients treated with fluoropyrimidines [J].

Cortejoso, Lucia ;

Garcia-Gonzalez, Xandra ;

Garcia, Maria I. ;

Garcia-Alfonso, Pilar ;

Sanjurjo, Maria ;

Lopez-Fernandez, Luis A. .

PHARMACOGENOMICS, 2016, 17 (09) :979-984

[5] METABOLISM OF PYRIMIDINE ANALOGS AND THEIR NUCLEOSIDES [J].

DAHER, GC ;

HARRIS, BE ;

DIASIO, RB .

PHARMACOLOGY & THERAPEUTICS, 1990, 48 (02) :189-222

[6] Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis [J].

Deenen, Maarten J. ;

Meulendijks, Didier ;

Cats, Annemieke ;

Sechterberger, Marjolein K. ;

Severens, Johan L. ;

Boot, Henk ;

Smits, Paul H. ;

Rosing, Hilde ;

Mandigers, Caroline M. P. W. ;

Soesan, Marcel ;

Beijnen, Jos H. ;

Schellens, Jan H. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (03) :227-U77

[7] DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients [J].

Del Re, Marzia ;

Cinieri, Saverio ;

Michelucci, Angela ;

Salvadori, Stefano ;

Loupakis, Fotios ;

Schirripa, Marta ;

Cremolini, Chiara ;

Crucitta, Stefania ;

Barbara, Cecilia ;

Di Leo, Angelo ;

Latiano, Tiziana Pia ;

Pietrantonio, Filippo ;

Di Donato, Samantha ;

Simi, Paolo ;

Passardi, Alessandro ;

De Braud, Filippo ;

Altavilla, Giuseppe ;

Zamagni, Claudio ;

Bordonaro, Roberto ;

Butera, Alfredo ;

Maiello, Evaristo ;

Pinto, Carmine ;

Falcone, Alfredo ;

Mazzotti, Valentina ;

Morganti, Riccardo ;

Danesi, Romano .

PHARMACOGENOMICS JOURNAL, 2019, 19 (06) :556-563

[8] Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity [J].

Meulendijks, Didier ;

Henricks, Linda M. ;

Jacobs, Bart A. W. ;

Aliev, Abidin ;

Deenen, Maarten J. ;

de Vries, Niels ;

Rosing, Hilde ;

van Werkhoven, Erik ;

de Boer, Anthonius ;

Beijnen, Jos H. ;

Mandigers, Caroline M. P. W. ;

Soesan, Marcel ;

Cats, Annemieke ;

Schellens, Jan H. M. .

BRITISH JOURNAL OF CANCER, 2017, 116 (11) :1415-1424

[9] Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data [J].

Meulendijks, Didier ;

Henricks, Linda M. ;

Sonke, Gabe S. ;

Deenen, Maarten J. ;

Froehlich, Tanja K. ;

Amstutz, Ursula ;

Largiader, Carlo R. ;

Jennings, Barbara A. ;

Marinaki, Anthony M. ;

Sanderson, Jeremy D. ;

Kleibl, Zdenek ;

Kleiblova, Petra ;

Schwab, Matthias ;

Zanger, Ulrich M. ;

Palles, Claire ;

Tomlinson, Ian ;

Gross, Eva ;

van Kuilenburg, Andre B. P. ;

Punt, Cornelis J. A. ;

Koopman, Miriam ;

Beijnen, Jos H. ;

Cats, Annemieke ;

Schellens, Jan H. M. .

LANCET ONCOLOGY, 2015, 16 (16) :1639-1650

[10] Safety of capecitabine: a review [J].

Mikhail, Sameh E. ;

Sun, Jun F. ;

Marshall, John L. .

EXPERT OPINION ON DRUG SAFETY, 2010, 9 (05) :831-841

← 1 2 →